While target-specific molecular glues like SMAPs are still in their early phase of development, our study suggests that combining PI3K/AKT/S6K1 pathway inhibitors with antiandrogen therapies cannot be ruled out in AR-addicted prostate cancer. Here, AKT1 is linked to prostate carcinoma.